New flavored chemo drink aims to ease treatment for kids with hard-to-treat cancers
NCT ID NCT04337177
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-phase study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the body processes the medicine. About 20 participants will take the drugs for five days in a row, and researchers will monitor side effects and drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Levine Children's Hospital - Carolinas Medical Center
Charlotte, North Carolina, 28204, United States
-
Children's Healthcare of Atlanta - Arthur M. Blank Hospital
Atlanta, Georgia, 30329, United States
-
Children's National Research Institute - Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039, United States
-
Duke University Children's Hospital and Health Center
Durham, North Carolina, 27710, United States
-
Indiana University School of Medicine, Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Phoenix Children's Hospital
Phoenix, Arizona, 85016, United States
-
Sarah Cannon Research Institute, Pediatric Hematology & Oncology
Nashville, Tennessee, 37203, United States
-
UCSF, Mission Bay - Benioff Children's Hospital
San Francisco, California, 94143, United States
-
University of North Carolina at Chapel Hill - North Carolina Cancer Hospital
Chapel Hill, North Carolina, 27514, United States
-
Washington University - St. Louis
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can the Body's own immune cells beat a recurrent brain tumor?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?